Trial
NCT06384820
Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Regeneron Pharmaceuticals
Collaborators
—
Condition
Cutaneous Squamous Cell Carcinoma
Intervention
cemiplimab
Why stopped
Business Decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-07-26